ABSTRACT
Clomiphene citrate (CC) was first introduced by Greenblatt et al. in 1961 and found to be a safe and efficient way to induce ovulation. The simplicity and inexpensive nature of this treatment have retained CC until today in its position as the first-line treatment for anovulation associated with normal concentrations of endogenous estrogens, (hypothalamic-pituitary dysfunction-WHO Group 2) mainly polycystic ovarian syndrome (PCOS).
